Cabergoline

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Cabergoline and local guidelines before prescribing.

Dopamine agonist (ergot-derived)

Mechanism

Long-acting dopamine D2 agonist reducing prolactin secretion.

Uses

Hyperprolactinaemia and prolactinoma, acromegaly adjunct, suppression of lactation.

Dosing

Side effects

Nausea, dizziness, headache, postural hypotension; psychiatric effects including impulse-control disorders; valvular fibrosis at high doses.

Interactions

Dopamine antagonists (antipsychotics, metoclopramide) oppose effect.

Contraindications and cautions

History of fibrotic disorders, cardiac valvulopathy

Monitoring

Prolactin, echocardiogram on long-term high dose

Pregnancy and breastfeeding

Stop at conception in most cases

Renal and hepatic impairment

Caution in severe liver disease

Overdose and reversal

Supportive; hypotension

Special advice

Echocardiography for long-term or high-dose use; monitor prolactin and tumour size.

More from the textbook: uses, cautions and other points
Where it is discussed in the book